UCB announced today that it has agreed to sell world-wide rights to its anti-haemorrhagic product Somatostatine-UCB to Eumedica.
Somatostatine-UCB is indicated for the treatment of acute upper gastrointestinal bleeding resulting from gastric and duodenal ulcers and other.
Somatostatine-UCB is being used in hospitals in more than 25 markets worldwide, for more than 20 years, especially in Western Europe. UCB’s world-wide 2008 net sales of Somatostatine-UCB were approx EUR11.4 million.
UCB receives a cash consideration of an industry average sales multiple for established products.
For more details, please click on the link below: